Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). (Q38949880)

7 September 2017

title

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). (English)

1 reference

7 September 2017

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

author name string

C W Kwok

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

O Treeck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

S Buchholz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

S Seitz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

O Ortmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

publication date

9 October 2014

1 reference

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

365-373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25293576 AND SRC:MED&resulttype=core&format=json

Treatment of triple negative breast cancer (TNBC): current options and future perspectives

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Hypothalamic hormones and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

LH-RH analogues: I. Their impact on reproductive medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Chemotherapy targeted to cancers through tumoral hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Drug combination studies and their synergy quantification using the Chou-Talalay method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

A user-friendly integrated monitor-adhesive patch for long-term ambulatory electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Triple-negative breast cancer--current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11523-014-0340-Y

Targeted chemotherapy for triple-negative breast cancers via LHRH receptor

21 January 2018

1 reference

12 December 2020

Primary and salvage therapy with LH-RH analogues in ovarian cancer.

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines

1 reference

12 December 2020

Current status of platinum-based antitumor drugs

1 reference

12 December 2020

Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition

1 reference

12 December 2020